Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-423-3p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RDM0021H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Whole blood, Cell culture lysates

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

25 – 0.78 amol/μl

Limit of Detection

0.26 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 4.7%

Inter-assay (Run-to-Run)

n = 5,
CV = 9.2%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay




  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-423-3p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic



MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-423 gene is located in frequently amplified region of the chromosome 17q11.2 and can produce two mature sequences: miR-423-3p and miR-423-5p. miR-423-3p is expressed in human promyelocytic leukemia cells (HL-60) and has been reported to act as an oncogene via promoting cell proliferation, cell cycle progression, clonogenicity, cell migration and invasion. The expression level of miR-423-3p has been observed to be increased in multiple cancer types, including breast cancer, hepatocellular carcinoma, endometrial carcinoma, and head and neck squamous cell carcinomas. Recent study also confirmed higher levels of several miRNAs including miR-423-3p in lung cancer samples in contrast with healthy controls. Thus, miR-423-3p has the potential to become a useful oncological biomarker.

Altered expression of miR-423-3p has been found in the kidney tissue, blood or urine of renal allograft recipients with acute rejection and fibrosis. miR-423-3p is involved in epithelial-mesenchymal transition signalling pathways promoting renal fibrosis.

Summary References (11)

References to miR-423-3p

  • LIN, Jun, et al. MicroRNA-423 promotes cell growth and regulates G 1/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis, 2011, 32.11: 1641-1647.
  • GUAN, Guofang, et al. microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. International journal of clinical and experimental pathology, 2014, 7.9: 5683
  • LIN, Jun, et al. MicroRNA-423 promotes cell growth and regulates G 1/S transition by targeting p21Cip1/Waf1 in hepatocellular carcinoma. Carcinogenesis, 2011, 32.11: 1641-1647.
  • LI, Hong-tao, et al. MiR-423-3p enhances cell growth through inhibition of p21Cip1/Waf1 in colorectal cancer. Cellular physiology and biochemistry, 2015, 37.3: 1044-1054.
  • ARRIOLA, Edurne, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory investigation, 2008, 88.5: 491.
  • FARAZI, Thalia A., et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer research, 2011, canres. 0608.2011.
  • BOREN, Todd, et al. MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecologic oncology, 2008, 110.2: 206-215.
  • HUI, Angela BY, et al. Comprehensive MicroRNA profiling for head and neck squamous cell carcinomas. Clinical cancer research, 2010, 16.4: 1129-1139.
  • ZHU, Ying, et al. Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p. Lung Cancer, 2017, 114: 6-11.
  • ANGLICHEAU, Dany, et al. MicroRNA expression profiles predictive of human renal allograft status. Proceedings of the National Academy of Sciences, 2009, 106.13: 5330-5335.
  • BEN-DOV, Iddo Z., et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation, 2012, 94.11.
Related Products Docs